Drug Research

Amgen is going ahead and adding Dark Blue to its tapestry, embedding the preclinical blood cancer program of U.K. biotech into its organization. The California pharma has gone ahead and stitched together a deal of almost $840 million for Dark Blue Therapeutics, which is...

Shortly after going ahead and securing a partnership with Sanofi, InduPro is now linking up with Eli Lilly in its endeavors to discover novel cancer treatments through a pact that could as well be worth almost $950 million. InduPro is...

Nimbus Therapeutics has announced that it has entered into a multi-year research partnership and a $1.3 billion exclusive license agreement with Eli Lilly in order to develop oral treatments in obesity as well as other metabolic diseases. Lilly, which very...

Sanofi and Earendil Labs have announced a strategic collaboration effort that goes on to apply the discovery platform from Earendil across many of the Sanofi autoimmune and inflammatory disease programs. The two AI-powered research and development platforms from Earendil Labs concerning protein therapeutics go on...

Insilico Medicine has gone ahead with a multi-year research and development - R&D collaboration with Servier, of almost $888m, in order to develop and discover certain new oncology therapies. The partnership combines the AI drug discovery platforms of Insilico...

The development of complex biological molecules requires a specialized toolkit distinct from traditional small-molecule chemistry. This article details the critical laboratory equipment—from advanced bioreactors to high-resolution characterization tools—that enables the precise engineering and rigorous analysis required for successful biologics and biosimilar innovation.

Advanced technologies such as AI-integrated high-throughput screening platforms and automated assay systems are fundamentally transforming early-stage pharmaceutical research. These innovations address critical bottlenecks in productivity and data quality, enabling research teams to accelerate timeline-to-candidate selection while enhancing the predictive accuracy of drug discovery campaigns.